首页> 外文期刊>Nature >The mitochondrial Na+/Ca2+ exchanger is essential for Ca2+ homeostasis and viability
【24h】

The mitochondrial Na+/Ca2+ exchanger is essential for Ca2+ homeostasis and viability

机译:线粒体Na + / Ca2 +交换子对于Ca2 +稳态和生存力至关重要

获取原文
获取原文并翻译 | 示例
           

摘要

Mitochondrial calcium (Ca-m(2+)) has a central role in both metabolic regulation and cell death signalling, however its role in homeostatic function and disease is controversial(1). Slc8b1 encodes the mitochondrial Na+/Ca2+ exchanger (NCLX), which is proposed to be the primary mechanism for mCa2+ extrusion in excitable cells(2,3). Here we show that tamoxifen-induced deletion of Slc8b1 in adult mouse hearts causes sudden death, with less than 13% of affected mice surviving after 14 days. Lethality correlated with severe myocardial dysfunction and fulminant heart failure. Mechanistically, cardiac pathology was attributed to mCa(2+) overload driving increased generation of superoxide and necrotic cell death, which was rescued by genetic inhibition of mitochondrial permeability transition pore activation. Corroborating these findings, overexpression of NCLX in the mouse heart by conditional transgenesis had the beneficial effect of augmenting mCa(2+) clearance, preventing permeability transition and protecting against ischaemia-induced cardiomyocyte necrosis and heart failure. These results demonstrate the essential nature of mCa(2+) efflux in cellular function and suggest that augmenting mCa(2+) efflux may be a viable therapeutic strategy in disease.
机译:线粒体钙(Ca-m(2+))在代谢调节和细胞死亡信号传导中都起着核心作用,但是其在体内稳态功能和疾病中的作用尚有争议(1)。 Slc8b1编码线粒体Na + / Ca2 +交换子(NCLX),被认为是可兴奋细胞中mCa2 +挤出的主要机制(2,3)。在这里,我们显示他莫昔芬诱导的成年小鼠心脏中Slc8b1的缺失导致猝死,不到13%的受影响小鼠在14天后存活。致命性与严重的心肌功能障碍和暴发性心力衰竭相关。从机理上讲,心脏病理学归因于mCa(2+)超载驱动增加的超氧化物和坏死细胞死亡的产生,这是通过线粒体通透性过渡孔激活的基因抑制来挽救的。证实这些发现,通过条件转基因在小鼠心脏中NCLX的过表达具有增加mCa(2+)清除率,防止渗透性转变并防止缺血引起的心肌细胞坏死和心力衰竭的有益作用。这些结果表明细胞功能中的mCa(2+)外排的本质,并建议增加mCa(2+)外排可能是疾病中可行的治疗策略。

著录项

  • 来源
    《Nature》 |2017年第7652期|93-97|共5页
  • 作者单位

    Temple Univ, Sch Med, Ctr Translat Med, Dept Pharmacol, Philadelphia, PA 19140 USA;

    Temple Univ, Sch Med, Ctr Translat Med, Dept Pharmacol, Philadelphia, PA 19140 USA;

    Temple Univ, Sch Med, Cardiovasc Res Ctr, Dept Physiol, Philadelphia, PA 19140 USA;

    Temple Univ, Sch Med, Ctr Translat Med, Dept Pharmacol, Philadelphia, PA 19140 USA;

    Temple Univ, Sch Med, Ctr Translat Med, Dept Pharmacol, Philadelphia, PA 19140 USA;

    Temple Univ, Sch Med, Ctr Translat Med, Dept Pharmacol, Philadelphia, PA 19140 USA;

    Ursinus Coll, Dept Hlth & Exercise Physiol, Collegeville, PA 19426 USA;

    Temple Univ, Sch Med, Ctr Translat Med, Dept Pharmacol, Philadelphia, PA 19140 USA;

    Temple Univ, Sch Med, Ctr Translat Med, Dept Pharmacol, Philadelphia, PA 19140 USA;

    Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA;

    Columbia Univ, Coll Phys & Surg, Dept Med, Div Cardiol, New York, NY 10032 USA;

    Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Howard Hughes Med Inst, Dept Pediat, Cincinnati, OH 45229 USA;

    Temple Univ, Sch Med, Cardiovasc Res Ctr, Dept Physiol, Philadelphia, PA 19140 USA;

    Temple Univ, Sch Med, Ctr Translat Med, Dept Pharmacol, Philadelphia, PA 19140 USA;

    Temple Univ, Sch Med, Cardiovasc Res Ctr, Dept Physiol, Philadelphia, PA 19140 USA;

    Temple Univ, Sch Med, Ctr Translat Med, Dept Pharmacol, Philadelphia, PA 19140 USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号